Anupam Rasayan India Ltd has acquired 100% of Mates Visa Consultancy Private Limited for ₹10,000. The move facilitates Anupam Rasayan's proposed acquisition of Bliss GVS Pharma Limited, acting as a 'person acting in concert'.
Anupam Rasayan Acquires Mates Visa Consultancy for ₹10,000
Anupam Rasayan India Ltd has acquired 1,000 equity shares, representing 100% of Mates Visa Consultancy Private Limited, for a cash consideration of ₹10,000. The face value per share was ₹10.
Reader Takeaway: Procedural acquisition for larger M&A; immaterial value.
What just happened
Anupam Rasayan India Ltd announced the completion of its acquisition of Mates Visa Consultancy Private Limited. The transaction involved purchasing all outstanding equity shares for a nominal amount. Mates Visa Consultancy, incorporated in May 2022, initially operated in visa and passport consultancy but will now align its business with Anupam Rasayan's operations and undergo a name change.
Why this matters
This acquisition is primarily a strategic maneuver to position Mates Visa Consultancy as a 'person acting in concert' (PAC) for Anupam Rasayan's larger, proposed acquisition of Bliss GVS Pharma Limited. This is in compliance with SEBI takeover regulations. The deal itself is financially insignificant for Anupam Rasayan, but it signals progress in the planned acquisition of Bliss GVS Pharma.
The backstory
Anupam Rasayan India Ltd is involved in the manufacturing of specialty chemicals. The company is also looking to expand its business through strategic acquisitions. Mates Visa Consultancy was incorporated recently in May 2022.
What changes now
The acquisition of Mates Visa Consultancy is a structural step. The target company will likely be used as a special-purpose vehicle to streamline the regulatory process for the acquisition of Bliss GVS Pharma. Investors should anticipate further announcements regarding the Bliss GVS Pharma deal.
Risks to watch
While this specific transaction carries minimal financial risk due to its small value, potential risks lie in the successful completion of the larger intended acquisition of Bliss GVS Pharma Limited, which is subject to regulatory approvals and market conditions.
Peer comparison
Anupam Rasayan operates in the specialty chemicals sector. Acquisitions by chemical companies can range from acquiring manufacturing facilities to securing market access or technology. This particular acquisition is unique as it serves a regulatory and procedural purpose for a subsequent, larger M&A activity.
Context metrics (time-bound)
Target Entity (Mates Visa Consultancy Private Limited) Turnover:
- FY 2023-24: ₹0.28 crore
- FY 2024-25: ₹0.29 crore
- FY 2025-26: ₹0.31 crore
What to track next
Investors should monitor updates on Anupam Rasayan's proposed acquisition of Bliss GVS Pharma Limited. The progress and outcome of that larger deal will be the key factor to watch, as this current acquisition is a preparatory step.